SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS

Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome

(2014) T-C Chen et al.   Blood Cancer Journal

Clinical implications of theSETBP1mutation in patients with primary myelodysplastic syndrome and its stability during disease progression

(2013) Hsin-An Hou et al.   AMERICAN JOURNAL OF HEMATOLOGY

The genetic basis of myelodysplasia and its clinical relevance

(2013) M. Cazzola et al.   BLOOD

Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice

(2013) J. Wang et al.   BLOOD

Clinical and biological implications of driver mutations in myelodysplastic syndromes

(2013) E. Papaemmanuil et al.   BLOOD

Smap1 deficiency perturbs receptor trafficking and predisposes mice to myelodysplasia

(2013) Shunsuke Kon et al.   JOURNAL OF CLINICAL INVESTIGATION

Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations

(2013) Daichi Inoue et al.   JOURNAL OF CLINICAL INVESTIGATION

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders

(2013) Tomoya Muto et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo

(2013) Omar Abdel-Wahab et al.   JOURNAL OF EXPERIMENTAL MEDICINE

SETBP1 mutation analysis in 944 patients with MDS and AML

(2013) F Thol et al.   LEUKEMIA

SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations

(2013) M Meggendorfer et al.   LEUKEMIA

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

(2013) T Haferlach et al.   LEUKEMIA

Somatic SETBP1 mutations in myeloid malignancies

(2013) Hideki Makishima et al.   NATURE GENETICS

Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10

(2012) K. Oakley et al.   BLOOD

ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression

(2012) Omar Abdel-Wahab et al.   CANCER CELL

Epigenetic aspects of MDS and its molecular targeted therapy

(2012) Jumpei Yamazaki et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

(2012) Rafael Bejar et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

(2012) Véronique Gelsi-Boyer et al.   Journal of Hematology & Oncology

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

(2012) Rocco Piazza et al.   NATURE GENETICS

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies

(2011) Z. Li et al.   BLOOD

Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation

(2011) Kelly Moran-Crusio et al.   CANCER CELL

Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes

(2011) Felicitas Thol et al.   JOURNAL OF CLINICAL ONCOLOGY

Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   JOURNAL OF CLINICAL ONCOLOGY

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect

(2011) I Cristóbal et al.   LEUKEMIA

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

(2011) Timothy A Graubert et al.   NATURE GENETICS

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of Leukocyte Mono-immunoglobulin-like Receptor 7 (LMIR7)/CLM-3 as an Activating Receptor

(2010) Yutaka Enomoto et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

(2009) I. Cristobal et al.   BLOOD

Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia

(2009) F. Nakahara et al.   BLOOD

Mutations of polycomb-associated geneASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia

(2009) Véronique Gelsi-Boyer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myelodysplastic syndromes

(2008) S. D. Nimer   BLOOD

Inhibition of the TGF-  receptor I kinase promotes hematopoiesis in MDS

(2008) L. Zhou et al.   BLOOD

AML1 mutations induced MDS and MDS/AML in a mouse BMT model

(2008) N. Watanabe-Okochi et al.   BLOOD

A tumor suppressor role for PP2A-B56α through negative regulation of c-Myc and other key oncoproteins

(2008) Hugh K. Arnold et al.   CANCER AND METASTASIS REVIEWS

The Organization of Histone H3 Modifications as Revealed by a Panel of Specific Monoclonal Antibodies

(2008) Hiroshi Kimura et al.   CELL STRUCTURE AND FUNCTION

Chromatin Immunoprecipitation on Microarray Analysis of Smad2/3 Binding Sites Reveals Roles of ETS1 and TFAP2A in Transforming Growth Factor   Signaling

(2008) D. Koinuma et al.   MOLECULAR AND CELLULAR BIOLOGY